Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 1:10 AM ET

Biotechnology

Company Overview of LiRIS Biomedical, Inc.

Company Overview

LiRIS Biomedical, Inc. operates as a pharmaceutical company. The company develops a portfolio of therapeutics to provide controlled-release of drugs directly to target tissues (bladders) to treat bladder diseases. It also offers LiRIS for the treatment of interstitial cystitis. The company was founded in 2008 and is based in Lexington, Massachusetts.

99 Hayden Avenue

Suite 100

Lexington, MA 02421

United States

Founded in 2008

Phone:

781-676-7750

Fax:

781-676-7788

Key Executives for LiRIS Biomedical, Inc.

Chief Executive Officer, President and Director
Co-Founder, Scientific Advisor and Director
Age: 55
Chief Financial Officer
Chief Business Officer and Senior Vice President
Chief Technology Officer
Compensation as of Fiscal Year 2015.

LiRIS Biomedical, Inc. Key Developments

Taris Biomedical Inc Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015

Taris Biomedical Inc Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 . Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

LiRIS Biomedical, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM

LiRIS Biomedical, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

TARIS BioMedical Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

TARIS Biomedical announced that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing the TARIS(R) proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. The TARIS(R) delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application. Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration. This could combine the ability to target both the right tissue - the tumour, with the right genetically targeted therapy and therefore represent a step change in the treatment of this disease.

Similar Private Companies By Industry

Company Name Region
Tonbo Biotechnologies Corporation United States
Glycobia, Inc. United States
Bio Balance, Inc. United States
Armune BioScience, Inc. United States
Atto BioScience, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 13, 2014
TARIS BioMedical, Inc., LiRIS Program in Phase 2
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LiRIS Biomedical, Inc., please visit www.tarisbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.